Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant

Infection

Volumn 46, Issue 2, 2018, Pages 263-265

  Peghin, Maddalena ^a   Maiani, Massimo ^b   Castaldo, Nadia ^a   Givone, Filippo ^a   Righi, Elda ^a   Lechiancole, Andrea ^b   Sartor, Assunta ^c   Pea, Federico ^c   Livi, Ugolino ^b   Bassetti, Matteo ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Ceftolozane tazobactam; Device infections; Heart transplant; Left ventricular assist device infection; MDR gram negative bacteria; MDR Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; COLISTIN; FLUORODEOXYGLUCOSE F 18; INOTROPIC AGENT; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; CASE REPORT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; DEVICE INFECTION; DISK DIFFUSION; DRUG WITHDRAWAL; EXTRACORPOREAL OXYGENATION; FEVER; HEART TRANSPLANTATION; HUMAN; LABORATORY TEST; LEFT VENTRICULAR APEX; LIVER FUNCTION TEST; MALE; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYOCARDITIS; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; STERNOTOMY; THORAX RADIOGRAPHY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; ADVERSE DEVICE EFFECT; ANALOGS AND DERIVATIVES; DRUG EFFECT; HEART ASSIST DEVICE; INFECTION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PROSTHESIS-RELATED INFECTIONS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 85032667796     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-017-1086-0     Document Type: Article

References (12)

1. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagace-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP 3rd, Karlowsky JA. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31–51.
2. Patel UC, Nicolau DP, Sabzwari RK. Successful treatment of multi-drug resistant Pseudomonas aeruginosa bacteremia with the recommended renally adjusted ceftolozane/tazobactam regimen. Infect Dis Ther. 2016;5:73–9.
3. Munita JM, Aitken SL, Miller WR, Perez F, Rosa R, Shimose LA, Lichtenberger PN, Abbo LM, Jain R, Nigo M, Wanger A, Araos R, Tran TT, Adachi J, Rakita R, Shelburne S, Bonomo RA, Arias CA. Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2017;. https://doi.org/10.1093/cid/cix014.
4. Cabot G, Bruchmann S, Mulet X, Zamorano L, Moya B, Juan C, Haussler S, Oliver A. Pseudomonas aeruginosa ceftolozane–tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother. 2014;58:3091–9.
5. Livermore DM, Mushtaq S, Meunier D, Hopkins KL, Hill R, Adkin R, Chaudhry A, Pike R, Staves P, Woodford N, Committee BRSS. Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles. J Antimicrob Chemother. 2017;. https://doi.org/10.1093/jac/dkx136.
6. Grupper M, Sutherland C, Nicolau DP. Multicenter evaluation of ceftazidime–avibactam and ceftolozane–tazobactam inhibitory activity against meropenem non-susceptible P. aeruginosa from blood, respiratory tract and wounds. Antimicrob Agents Chemother. 2017;. https://doi.org/10.1128/AAC.00875-17.
7. Dassner AM, Sutherland C, Girotto J, Nicolau DP. In vitro activity of ceftolozane/tazobactam alone or with an aminoglycoside against multi-drug-resistant Pseudomonas aeruginosa from pediatric cystic fibrosis patients. Infect Dis Ther. 2017;6:129–36.
8. Nienaber JJ, Kusne S, Riaz T, Walker RC, Baddour LM, Wright AJ, Park SJ, Vikram HR, Keating MR, Arabia FA, Lahr BD, Sohail MR, Mayo Cardiovascular Infections Study Group. Clinical manifestations and management of left ventricular assist device-associated infections. Clin Infect Dis. 2013;57:1438–48.
9. Akin S, Muslem R, Constantinescu AA, Manintveld OC, Birim O, Brugts JJ, Maat AP, Froberg AC, Bogers AJ, Caliskan K. 18F-FDG PET/CT in the diagnosis and management of continuous flow left ventricular assist device infections: a case series and review of the literature. ASAIO J. 2017;. https://doi.org/10.1097/MAT.0000000000000552.
10. Velez Perez AL, Schmidt-Malan SM, Kohner PC, Karau MJ, Greenwood-Quaintance KE, Patel R. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states. Diagn Microbiol Infect Dis. 2016;85:356–9.
11. Jones BM, Smith B, Bland CM. Use of continuous-infusion ceftolozane/tazobactam in a multidrug-resistant Pseudomonas aeruginosa urinary tract infection in the outpatient setting. Ann Pharmacother. 2017;51:715–6.
12. Gentile I, Buonomo AR, Maraolo AE, Scotto R, De Zottis F, Di Renzo G, Borgia G. Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy. J Antimicrob Chemother. 2017;. https://doi.org/10.1093/jac/dkx172.